ClinicalTrials.gg
Active, not recruitingNCT02239783Updated Nov 18, 2023

Post Market Clinical Follow-Up Study Protocol for PROFEMUR® TL Modular Femoral Stems

An observational study in Joint Disease, sponsored by MicroPort Orthopedics Inc.. Active, not recruiting at 1 site in Canada. Open to participants aged 21 Years and older. Per ClinicalTrials.gov, last updated 2023-11-18.

Sponsored by MicroPort Orthopedics Inc. (part of MicroPort Scientific Corporation) · Observational

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
143
Ages
21 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 21 studies in Joint Diseases by MicroPort Scientific Corporation — 5 open to participants now, 13 under way, none of them phase 3. Joint Diseases · MicroPort Scientific Corporation.

Planned enrollment
5th of 20
143 · median 69
Started
2014
with 4 others
Observational
20 of 21
5 open now
Primary completion
2027-11
later than 3 of 12 live
Registered
2nd of 21
by date

Among the 21 studies in Joint Diseases by MicroPort Scientific Corporation, this one is the 5th largest by planned enrollment of the 20 observational ones that give a count, is one of 5 that started in 2014, is one of 20 observational ones, reaches primary completion later than 3 of the 12 other live ones, and was the 2nd registered.

Joint Diseases

386 studies on the registry are indexed under Joint Diseases; 64 are open to participants now.

Browse Joint Diseases studies →

Open to participants now

5 of the 21 studies in Joint Diseases by MicroPort Scientific Corporation are open now, in 5 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

Who these studies take

Of the 44 Joint Diseases studies recruiting now, 24 (55%) set no upper age limit and 11 (25%) stop at 75 or younger; 3 take children under 18; 1 takes healthy volunteers.

This study: 21 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 21 studies in Joint Diseases by MicroPort Scientific Corporation, or all of them as a file.
02

Study summary

Sponsor is conducting this post market clinical follow-up (PMCF) study to evaluate the safety and efficacy of its total hip arthroplasty (THA) marketed in the European Union (EU) . These types of studies are required by regulatory authorities for all THA devices that do not have clinical evidence available at the time of gaining approval to market in the EU. This study has been designed in accordance with MEDDEV 2.12/2 rev 2.

Read the detailed description

Total hip arthroplasty (THA) has been performed since the early 1920s and is generally considered to be one of the most successful orthopedic surgeries performed. The 8th Annual Report from the National Joint Registry of England and Wales reported 95.3% component survivorship at 7 years for over 300,000 THA implantations. MicroPort Orthopedics, Inc. (MPO) currently markets several THA components throughout the world, including the European Union (EU). As part of the process for gaining approval to market in the EU, MPO is conducting this post market clinical follow-up (PMCF) study to evaluate the safety and efficacy of these THA components. The objectives of this study are to evaluate component survivorship and total functional outcome scores of implanted subjects at out to 10 years follow-up.

03

Conditions studied

  • Joint Disease

Keywords

  • osteoarthritis
  • avascular necrosis
  • ankylosis
  • protrusio acetabuli
  • painful hip dysplasia
  • rheumatoid arthritis
  • correction of functional deformity
  • revision procedures
04

Who can participate

Ages eligible
21 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Patients who have been previously implanted with a primary PROFEMUR® TL Modular Femoral Stem

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Has undergone primary THA for any of the following:
  • Non-inflammatory degenerative joint disease such as osteoarthritis, avascular necrosis, ankylosis, protrusio acetabuli, or painful hip dysplasia;
  • Inflammatory degenerative joint disease such as rheumatoid arthritis; or
  • Correction of functional deformity
  • Subject is implanted with the specified combination of components
  • Subject is willing and able to complete required study visits or assessments

Exclusion criteria

Exclusion Criteria:

  • Subjects implanted with DYNASTY® BIOFOAM® Acetabular Shells
  • Subjects implanted with a metal-on-metal articulation
  • Subjects implanted with non-MicroPort Orthopedics components (femoral heads, acetabular shells, acetabular liners) in the enrolled THA
  • Subjects skeletally immature (less than 21 years of age) at time of primary THA surgery
  • Subjects currently enrolled in another clinical study which could affect the endpoints of this protocol
  • Subjects unwilling to sign the document
  • Subjects with substance abuse issues
  • Subjects who are incarcerated or have pending incarceration
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
143 participants (estimated)
Patient registry
No

Groups and cohorts

  • Total Hip Arthroplasty

    Single group previously implanted with the following combination of components: PROFEMUR® TL modular femoral stem, MicroPort Orthopedics acetabular shell, MicroPort Orthopedics polyethylene or ceramic liner, MicroPort Orthopedics metal or ceramic femoral head.

    Device: total hip arthroplasty implant

Interventions

  • Devicetotal hip arthroplasty implant

    Also known as: PROFEMUR® TL modular femoral stem

06

What researchers measure

Primary outcomes

  1. Component Survivorship

    The primary objective of this study is to estimate component survivorship of all components out to 10 years follow-up.

    Time frame: 10 years post-operative

Secondary outcomes

  1. Patient functional outcomes

    The secondary objective is to characterize total functional scores, as assessed by HOOS scores and EQ-5D-3L scores.

    Time frame: Screening (First Available), 2-5 years, 5-7 years, and 10 years

07

Study locations

1 site
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Nov 2014 (actual). Primary completion is estimated for Nov 2027, 156 months after the start.

Of 58 observational studies under Joint Diseases, half reached primary completion within 63 months of starting (the median), counting those still running; a quarter within 28 and three quarters within 153. This study's planned 156 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 11, 2014
First posted
Sep 15, 2014
StartActual
Nov 2014
Primary completionEst.
Nov 2027
CompletionEst.
Nov 2028
Last update
Nov 18, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 18, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT02239783
Responsible party
Sponsor
First posted
Sep 15, 2014
Start date
Nov 2014
Primary completion
Nov 2027 (estimated)
Completion
Nov 2028 (estimated)
Last update
Nov 18, 2023

Study contacts

Paul Beaule, MD
principal investigator · Ottawa Hospital Research Institute

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Nov 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion